GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (NAS:PCVX) » Definitions » Return-on-Tangible-Asset

Vaxcyte (Vaxcyte) Return-on-Tangible-Asset : -21.72% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vaxcyte's annualized Net Income for the quarter that ended in Mar. 2024 was $-380.08 Mil. Vaxcyte's average total tangible assets for the quarter that ended in Mar. 2024 was $1,749.61 Mil. Therefore, Vaxcyte's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -21.72%.

The historical rank and industry rank for Vaxcyte's Return-on-Tangible-Asset or its related term are showing as below:

PCVX' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -73.66   Med: -36.25   Max: -27.91
Current: -29.1

During the past 6 years, Vaxcyte's highest Return-on-Tangible-Asset was -27.91%. The lowest was -73.66%. And the median was -36.25%.

PCVX's Return-on-Tangible-Asset is ranked better than
58.16% of 1551 companies
in the Biotechnology industry
Industry Median: -40.12 vs PCVX: -29.10

Vaxcyte Return-on-Tangible-Asset Historical Data

The historical data trend for Vaxcyte's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Return-on-Tangible-Asset Chart

Vaxcyte Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -73.66 -38.91 -27.91 -33.59 -33.33

Vaxcyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.01 -21.77 -24.72 -49.81 -21.72

Competitive Comparison of Vaxcyte's Return-on-Tangible-Asset

For the Biotechnology subindustry, Vaxcyte's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vaxcyte's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxcyte's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Vaxcyte's Return-on-Tangible-Asset falls into.



Vaxcyte Return-on-Tangible-Asset Calculation

Vaxcyte's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-402.266/( (1006.178+1407.917)/ 2 )
=-402.266/1207.0475
=-33.33 %

Vaxcyte's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-380.08/( (1407.917+2091.305)/ 2 )
=-380.08/1749.611
=-21.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Vaxcyte  (NAS:PCVX) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Vaxcyte Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Vaxcyte's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Vaxcyte (Vaxcyte) Business Description

Traded in Other Exchanges
Address
825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.
Executives
Andrew Guggenhime officer: CFO, CBO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Grant Pickering director, officer: President & CEO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Mikhail Eydelman officer: SVP, Gen Counsel & Corp Sec C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jim Wassil officer: Chief Operating Officer C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Heath Lukatch director 326 BOLLAY DRIVE, GOLETA CA 93117
Elvia Cowan officer: See Remarks Section C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jeff Fairman officer: VP, Research C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Paul Sauer officer: SVP Process Dev, Manufacturing C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404
Michael E. Kamarck director C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Carlos V Paya director C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Harpreet S. Dhaliwal officer: SVP Cml Mfg & Supply Chain C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Anne S Drapeau director C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110
Teri Loxam director C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Jane Wright Mitchell officer: General Counsel C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Robert Lorne Hopfner director C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111